Johnson & Johnson Shows Growth Despite Challenges

Johnson & Johnson continues to grow despite market challenges, maintaining its position as a defensive anchor with 60 years of rising dividends and market leadership in three-quarters of its core areas. The company is seeing record adoption of new medications, even with a significant sales decline for its blockbuster drug Stelara.